Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...
During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Vertex ( (VERX)) has shared an update. On ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A former executive at Microsoft ...
Vertex Pharmaceuticals (VRTX) plunged after Q2 earnings and is now down 21% over the past year. The company has historically had a strong R&D pipeline and has consistently been a winner, but the ...
The acquisition of Adams marks Vertex’s seventh acquisition under Wind Point ownership Jeff Christmann serves as CEO of Adams The Vertex Companies, a portfolio company of Wind Point Partners, has ...
NEW YORK and ROME, Ga., Aug. 5, 2025 /PRNewswire/ -- The VERTEX Companies, LLC ("VERTEX"), a global professional services firm delivering expert, forensic, construction project advisory, and ...
Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...
Aug 4 (Reuters) - Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage trial failure and will not start a study for expanded use of ...
Vertex Pharmaceuticals’VRTX-1.24%decrease; red down pointing triangle stock fell in post-market trading Monday, after the company said it would not progress a next-generation pain treatment into ...
Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators said they didn’t see a path forward for broad use of its pill in treating a ...
OF THE AREA MEDIAN INCOME. A GLOBAL BIOTECH COMPANY IS FOSTERING TALENT AMONG BOSTON PUBLIC SCHOOL KIDS. OUR ERIKA TARANTAL REPORTS ON THE PAID INTERNSHIP PROGRAM, GIVING STUDENTS THE OPPORTUNITY OF A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback